Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer.

Ozaslan E, Topaloglu US, Inanc M, Gokmen Erdem U, Demir H, Arpaci E, Metin Seker M, Karaagac M, Kiziltepe M, Eker B, Ozkan M.

J BUON. 2017 Jul-Aug;22(4):863-868.

2.

Metabolic Effects of Antidepressant Treatment.

Olguner Eker Ö, Özsoy S, Eker B, Doğan H.

Noro Psikiyatr Ars. 2017 Mar;54(1):49-56. doi: 10.5152/npa.2016.12373. Epub 2017 Mar 1.

3.

Assessment of Factors Related to the Understanding of Education and Knowledge of Self-Care among Patients with Diabetes Mellitus: A Cross-Sectional Prospective Study.

Dizdar OS, Gul OO, Baspınar O, Cander S, Sisman P, Eker B, Ersoy C.

Adv Ther. 2016 Sep;33(9):1565-78. doi: 10.1007/s12325-016-0378-6. Epub 2016 Jul 11.

PMID:
27397589
4.

Primary Pleomorphic Rhabdomyosarcoma of Thyroid Gland in an Adult Patient: A Case Report.

Ozaslan E, Berk V, Baldane S, Eker B, Bozkurt O, Senol S, Duran AO, Cubukcu G, Karaca H, Ozkan M.

Eurasian J Med. 2016 Feb;48(1):69-72. doi: 10.5152/eurasianjmed.2015.96.

5.

Are Rogerofenib and Nilotinib Effective for Advanced Gastrointestinal Stromal Tumor (GIST) Patients who have Already been Given Main Treatments?

Ozaslan E, Ozkan M, Bozkurt O, Duran AO, Ucar M, Eker B, Berk V, Karaca H.

Asian Pac J Cancer Prev. 2015;16(11):4801-2. No abstract available.

6.

Factors affecting prognosis in metastatic colorectal cancer patients.

Eker B, Ozaslan E, Karaca H, Berk V, Bozkurt O, Inanc M, Duran AO, Ozkan M.

Asian Pac J Cancer Prev. 2015;16(7):3015-21.

7.

Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer.

Bozkurt O, Inanc M, Turkmen E, Karaca H, Berk V, Duran AO, Ozaslan E, Ucar M, Hacibekiroglu I, Eker B, Baspinar O, Ozkan M.

Asian Pac J Cancer Prev. 2014;15(21):9277-81.

8.

Heterogeneous integration of gels into microfluidics using a mesh carrier.

Eker B, Temiz Y, Delamarche E.

Biomed Microdevices. 2014 Dec;16(6):829-35. doi: 10.1007/s10544-014-9886-9.

PMID:
24999091
9.

Label-free recognition of drug resistance via impedimetric screening of breast cancer cells.

Eker B, Meissner R, Bertsch A, Mehta K, Renaud P.

PLoS One. 2013;8(3):e57423. doi: 10.1371/journal.pone.0057423. Epub 2013 Mar 4.

10.

A supramolecular approach to enzyme immobilization in micro-channels.

González-Campo A, Eker B, Gardeniers HJ, Huskens J, Jonkheijm P.

Small. 2012 Nov 19;8(22):3531-7. doi: 10.1002/smll.201200565. Epub 2012 Aug 7.

PMID:
22887837
11.

A microfluidic-based frequency-multiplexing impedance sensor (FMIS).

Meissner R, Joris P, Eker B, Bertsch A, Renaud P.

Lab Chip. 2012 Aug 7;12(15):2712-8. doi: 10.1039/c2lc40236j. Epub 2012 May 25.

PMID:
22627460
12.

A supramolecular sensing platform for phosphate anions and an anthrax biomarker in a microfluidic device.

Eker B, Yilmaz MD, Schlautmann S, Gardeniers JG, Huskens J.

Int J Mol Sci. 2011;12(11):7335-51. doi: 10.3390/ijms12117335. Epub 2011 Oct 26.

13.

Distinguishing drug-induced minor morphological changes from major cellular damage via label-free impedimetric toxicity screening.

Meissner R, Eker B, Kasi H, Bertsch A, Renaud P.

Lab Chip. 2011 Jul 21;11(14):2352-61. doi: 10.1039/c1lc20212j. Epub 2011 Jun 6.

PMID:
21647498
14.

Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing.

Krummel B, Strassburg A, Ernst M, Reiling N, Eker B, Rath H, Hoerster R, Wappler W, Glaewe A, Schoellhorn V, Sotgiu G, Lange C.

PLoS One. 2010 Jul 20;5(7):e11670. doi: 10.1371/journal.pone.0011670.

15.

What about existing databases?

Herzmann C, Günther G, Eker B, Lange C, Migliori GB.

Dtsch Arztebl Int. 2010 Jun;107(24):435-6; author reply 436. doi: 10.3238/arztebl.2010.0435c. Epub 2010 Jun 18. No abstract available.

16.

ENZYMATIC POLYMERIZATION OF PHENOLS IN ROOM TEMPERATURE IONIC LIQUIDS.

Eker B, Zagorevski D, Zhu G, Linhardt RJ, Dordick JS.

J Mol Catal B Enzym. 2009 Jul;59(1=3):177-184.

17.

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Sotgiu G, Lange C, Richardson MD, Matteelli A, Centis R, Eker B, Guenther G, Spanevello A, Migliori GB; TBNET.

J Antimicrob Chemother. 2009 Oct;64(4):879-83; author reply 883-4. doi: 10.1093/jac/dkp265. Epub 2009 Aug 3. No abstract available.

PMID:
19651787
18.

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C; TBNET Study Group.

Eur Respir J. 2009 Aug;34(2):387-93. doi: 10.1183/09031936.00009509. Epub 2009 Mar 12.

19.

Multidrug- and extensively drug-resistant tuberculosis, Germany.

Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group.

Emerg Infect Dis. 2008 Nov;14(11):1700-6. doi: 10.3201/eid1411.080729.

20.

Enzyme-carbon nanotube conjugates in room-temperature ionic liquids.

Eker B, Asuri P, Murugesan S, Linhardt RJ, Dordick JS.

Appl Biochem Biotechnol. 2007 Nov;143(2):153-63.

PMID:
18025604

Supplemental Content

Support Center